Company news

Moderna, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union

July 21, 2022

Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)

July 13, 2022

Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022

July 12, 2022

Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215

July 11, 2022

Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5

June 21, 2022

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

June 20, 2022

Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

June 16, 2022

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

June 7, 2022

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

June 6, 2022

Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

June 1, 2022

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

May 30, 2022

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

May 16, 2022

Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer

May 10, 2022

Moderna to Host Annual Science and Technology Day on May 17, 2022

May 8, 2022

Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates

May 3, 2022

Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

April 28, 2022

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

April 27, 2022

Arpa Garay Joins Moderna as Chief Commercial Officer

April 26, 2022

Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform

April 18, 2022

Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022

April 12, 2022

Jorge Gomez Joins Moderna as Chief Financial Officer

April 10, 2022

Moderna Launches New Charitable Foundation

April 3, 2022

Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273

March 28, 2022

Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day

March 23, 2022

Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

March 22, 2022

Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day

March 21, 2022

Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine

March 20, 2022

Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

March 16, 2022

Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine

March 15, 2022

Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine

March 13, 2022

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

March 9, 2022

Moderna Announces Its Global Public Health Strategy

March 6, 2022

Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia

March 2, 2022

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates

February 23, 2022

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

February 22, 2022

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

February 21, 2022

Moderna Expands Its mRNA Pipeline with Three New Development Programs

February 17, 2022

Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

February 15, 2022

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

February 14, 2022

Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine

February 7, 2022

Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

February 2, 2022

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax

January 30, 2022

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant

January 25, 2022

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update

January 9, 2022

Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

January 4, 2022

Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022

December 26, 2021

Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

December 19, 2021

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea

December 13, 2021

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

December 12, 2021

Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

December 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 63 decks. Every deck is listed under its year.